Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with advanced liver cancer.
Full description
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients undergo hypofractionated stereotactic radiotherapy once daily on days 1-5.
After completion of study therapy, patients are followed at 1 and 3 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
No known CNS tumors, including metastatic brain disease
No malignancy within the past 3 years that is distinct in its primary site or histology from HCC, except for carcinoma in situ of the cervix, treated basal cell carcinoma, or superficial bladder tumors (i.e., Ta, Tis, and T1), or any other cancer that has been curatively treated > 3 years prior to study entry
No renal failure requiring hemodialysis or peritoneal dialysis
No uncontrolled intercurrent illness including, but not limited to, any of the following:
Condition that could jeopardize the safety of the patient or study compliance
No history of variceal bleeding where the varices have not been eradicated or decompressed by shunt placement
No condition that would prevent the patient from undergoing marker implantation
Not pregnant or nursing/negative pregnancy test
No substance abuse, medical, psychological, or social condition that may interfere with the patient's participation in the study or evaluation of the study results
No prior radiotherapy to the liver
Primary purpose
Allocation
Interventional model
Masking
9 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal